RxDoctor Payments Data

Mariselly Medina Irizarry, MD

Pulmonary Disease · Orlando, FLNPI 1144209669

Payments from drug & device makers

$4,619in general payments, 2019–2025

Across 256 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$531
  • Mylan Specialty L.p.$238
  • Boehringer Ingelheim$231
  • Regeneron Healthcare Solutions, Inc.$149
  • Grifols USA, LLC$148
  • plus $746 from 19 others

What the payments were for

  • Food & beverage$4,619100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,619 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$56,751
Medicare patients
158
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter348$290,882
Breo ElliptaFluticasone/Vilanterol57$43,636
Dupixent PenDupilumab12$41,207
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$31,302
Spiriva RespimatTiotropium Bromide37$29,284
SymbicortBudesonide/Formoterol Fumarate75$23,218
Arnuity ElliptaFluticasone Furoate95$23,051
Albuterol Sulfate HfaAlbuterol Sulfate339$10,747
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$8,360
Advair HfaFluticasone Propion/Salmeterol18$7,646
BreynaBudesonide/Formoterol Fumarate26$6,508
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,721
Atrovent HfaIpratropium Bromide12$5,545
Fluticasone-VilanterolFluticasone/Vilanterol11$4,790
Wixela InhubFluticasone Propion/Salmeterol27$4,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$2,575$365,929517 claims
AstraZenecaBreztri Aerosphere, Symbicort$531$54,520115 claims
Boehringer IngelheimSpiriva Respimat$231$29,28437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →